The treatment of COVID-19
Monoclonal antibody sotrovimab
Assist. Prof. Aleksandra Maršavelski, PhD
Specialist in computational biochemistry
* Monoclonal antibody sotrovimab receives Emergency Use Authorization from the US FDA for the treatment of COVID-19
GlaxoSmithKline and Vir Biotechnology have developed monoclonal antibody therapy with sotrovimab (VIR-7831 and GSK4182136) for the treatment of COVID-19. The US Food and Drug Administration (FDA) approved on May 26 the possibility of emergency use of sotrovimab for the treatment of moderate COVID-19 in people at high risk of progression to a severe COVID-19.
In a clinical trial, the use of sotrovimab resulted in an 85% reduction in the risk of hospitalization and a reduced number of deaths in adults with a severe COVID-19 when compared to placebo.
Laboratory studies have shown that sotrovimab is also effective against the SARS-CoV-2 mutations – including one discovered in the UK, South Africa, Brazil and India.
Please follow the link below for further information